IndustryCompany release

Krystal Biotech's VYJUVEK Sales Reach $127.3M in Q3 as Board Approves $400M Buyback

🇺🇸 Krystal Biotech, Inc. (KRYS) · Mon 02 Nov 2026

The company also reported finished pricing talks in Germany and Italy, an Australian filing, and early lesion regression in three Gorlin syndrome patients treated with KB113.

Krystal Biotech reported third-quarter 2026 results on 2 November, with global net revenue from VYJUVEK (B-VEC), its treatment for dystrophic epidermolysis bullosa, reaching $127.3M. The company said this was a 30% increase on the same period a year earlier.

On the market-access side, pricing negotiations for VYJUVEK have been completed in Germany and Italy. Krystal expects to launch the product in Italy in early 2027. The company has also submitted a marketing application in Australia.

The board approved a share repurchase programme of up to $400M. The summary provided does not give a timetable or the mechanics of the buyback.

In its pipeline, Krystal is in discussions with the US Food and Drug Administration about developing KB113 for basal cell carcinoma in patients with Gorlin syndrome. The talks follow a pilot study in three patients, which showed regression of lesions. Because of the small size of the pilot, the findings are early and preliminary.

What it means for your team

  • Market-access teams should note that German and Italian pricing talks for VYJUVEK are complete, with Italian launch expected in early 2027.
  • Regulatory teams may want to track the Australian marketing application for VYJUVEK, as no decision timeline was given.
  • The KB113 programme for Gorlin syndrome is at an early stage, with FDA discussions under way after a three-patient pilot; no formal development plan has been described.

Company's press release (SEC filing): Krystal Biotech, Inc. ↗

Article written by VigiEye from the official source (Krystal Biotech, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →